Dasatinib

目录号:S1021 别名: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib是一种新型有效的多靶点抑制剂,作用于AblSrc和 c-Kit,在无细胞试验中IC50分别为 <1 nM,0.8 nM 和 79 nM。

规格 价格 库存 购买数量  
In DMSO RMB 1142.64 现货
RMB 1224.97 现货
RMB 3039.93 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献220篇:

产品安全说明书

Src抑制剂选择性比较

生物活性

产品描述 Dasatinib是一种新型有效的多靶点抑制剂,作用于AblSrc和 c-Kit,在无细胞试验中IC50分别为 <1 nM,0.8 nM 和 79 nM。
靶点
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
体外研究

在抑制表达野生型Bcr-Abl或全部Bcr-Abl突变型(除了T315I)的Ba/F3增殖时,Dasatinib效果比Imatinib高很多。与Imatinib相比,Dasatinib呈2倍指数增长效力(约325倍)。Dasatinib有效抑制野生型Abl 激酶和全部突变型(除了T315I)。Dasatinib 直接靶向作用于野生型和突变型Abl激酶域,且抑制自磷酸化和底物磷酸化,这种作用存在浓度依赖性。Dasatinib作用于表达野生型 Bcr-Abl的细胞时,效果比Imatinib高325倍多。[1] TgE骨髓细胞菌落百分数从未处理孔的100% 降低到Dasatinib处理孔的4.12%。 有 Dasatinib存在时, WT 和TgE骨髓细胞形成的菌落百分数明显不同。LMP2A的表达可促进 B 淋巴细胞存活和增殖,而Dasatinib通过靶向作用于Lyn 和/或c-Abl 激酶可抑制以上存活和增殖。[2] Dasatinib 处理一系列甲状腺癌细胞,抑制Src信号, 降低生长速度,使细胞周期停滞,且诱导凋亡。使用剂量不断增加的 Dasatinib (0.019 μM 到 1.25 μM) 处理C643, TPC1, BCPAP, 和 SW1736 细胞3天,抑制50%细胞生长,然而抑制K1细胞系生长则需更高浓度Dasatinib。使用10 nM 或50 nM Dasatinib 处理BCPAP,SW1736 和 K1 细胞,导致G1期细胞提高9-22%,而S期细胞百分数则降低7-18%。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HpSVczKGh? MnvJSG1UVw>? MkfxTWM2OD1yLkCwNFA4KM7:TR?= NUDZSpB1OTd7NU[wPFA>
K562 M{XRXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXEOZk4OiCq M2f3cWROW09? NYnvN4JuUUN3ME2wMlAxOSEQvF2= MVOxO|k2PjB6MB?=
M07e MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnXSHlqPzJiaB?= MYPEUXNQ Mo\DTWM2OD1yLkCwNVIh|ryP NWKwVop1OTd7NU[wPFA>
ALL3 MXTDfZRwfG:6aXOgRZN{[Xl? NXH4O|RXOC5zzszN Mn7oO|IhcA>? MnTwSG1UVw>? MojmTWM2OD1yLkCwNFQh|ryP NXjhcXBHOTl6OEm1OFA>
CML NWXyZZNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGP4fHAzOCCvaX6= NEHib4lFVVOR NH7jPYdKSzVyPUCuNFAyKM7:TR?= MnTQNVkzOTlyMU[=
BA/F3 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELZOZY4OiCq NUHxcHplTE2VTx?= MnfpTWM2OD14LkW4PUDPxE1? MVGyN|A5QDZ2NB?=
BA/F3 M17tUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LOVlczKGh? NWjVW5pwTE2VTx?= NVe0bVBPUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBOOzVzVDDteZRidnRid3n0bEBKSzVyIH;mJFAvODByOEROwG0> M4TBblI{ODh6NkS0
BA/F3 Ml;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\5bWo4OiCq MXfEUXNQ MUPJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzD3bYxlKHS7cHWgRoNzNUGkbDD3bZRpKEmFNUCgc4YhOC5yMES1{txO NVv5ZlJTOjNyOEi2OFQ>
BA/F3 MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnxU|c3PzJiaB?= NULWc3F1TE2VTx?= MkDQTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3OrbnegRoNzNUGkbDDUN|E2USCvdYThcpQhf2m2aDDJR|UxKG:oIEGuO|E1|ryP NUnidZpjOjNyOEi2OFQ>
BA/F3 NF\PZmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXi3NkBp NX;o[YVuTE2VTx?= MnnxTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTjR6NmOgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNFnPxE1? NFHMS5YzOzNyMUewNy=>
BA/F3 NIDz[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PFRlczKGh? MlniSG1UVw>? MWHJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBGOjV3SzDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECzNu69VQ>? M4LpdlI{OzBzN{Cz
BA/F3 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjmO|IhcA>? M{m3cGROW09? NIjvT5JKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCJMkWwSUBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA2Oc7:TR?= MVmyN|MxOTdyMx?=
BA/F3 MlHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPhZ3g4OiCq MYrEUXNQ NWXMRZR[UW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiUUK1NmghdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxQM7:TR?= M1X4ZlI{OzBzN{Cz
BA/F3 M3rMeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnyzO|IhcA>? NXXRNldZTE2VTx?= NEfxN5NKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCHM{W5WkBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFAyO87:TR?= M3y0[FI{OzBzN{Cz
BA/F3 M1W5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW[3NkBp NUj6d5dMTE2VTx?= NV;SNJBjUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIIfpcIQhfHmyZTDCR3IuSUKOIHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNVnPxE1? NUHQToM5OjN|MEG3NFM>
BA/F3 NXrUXIp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17DUVczKGh? Mnv6SG1UVw>? MXrJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEB[OjV|SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECyN:69VQ>? MUiyN|MxOTdyMx?=
BA/F3 NVnwbYtLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPJO|IhcA>? NVPxcFhuTE2VTx?= MkmxTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhXDNzNVmgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iB|LkdOwG0> M4nwTlI{OzBzN{Cz
BA/F3 NXi4do1wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWm3NkBp MmTPSG1UVw>? Moj6TY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghUW6qaXLpeIlwdiC5aYToJGlEPTBib3[gNk42|ryP NX\zd5hzOjN|MEG3NFM>
T cell MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzhO|IhcA>? MXLEUXNQ MWTJcohq[mm2czDhcpRqKEOGMz2gZY5lKGGwdHmgR2QzQC2rbnT1Z4VlKFRiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjByM988US=> M4j6eFE4OTV2NUGy
WiDr M2HuRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLQcYU{PzJiaB?= NHP4dVhFVVOR Mo\QTWM2OD1yLkC1NkDPxE1? NIHqbW8yPTZzNUWxNi=>
PC3 NGSwXmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLhO|IhcA>? MoTuSG1UVw>? NYjpR5ZmUUN3ME2wMlAxQTRizszN M{jXeFE2PjF3NUGy
MDA-MB-231 M3PYdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWq1[pQzPzJiaB?= NFW4eGlFVVOR MlrkTWM2OD1yLkCxNkDPxE1? NVnaSlJmOTV4MUW1NVI>
Hs578T NIrlV5NEgXSxdH;4bYMhSXO|YYm= MmfPO|IhcA>? NWfRcZA6TE2VTx?= M1Xae2dKPTB;MD6wN{DPxE1? NIjNfVEzPDBzNUOyOy=>
HMEC NXfIXHZ3S3m2b4TvfIlkKEG|c3H5 MWm3NkBp MoD5SG1UVw>? MVHHTVUxRTFwODFOwG0> M33PR|I1ODF3M{K3
DU145 NXzZVFF6S3m2b4TvfIlkKEG|c3H5 M1vsXVczKGh? MnT5SG1UVw>? M1nnZmdKPTB;MD6xOkDPxE1? NVHoT5VUOjRyMUWzNlc>
U251 M1vEdWN6fG:2b4jpZ{BCe3OjeR?= M{n0XFczKGh? MkG5SG1UVw>? NUXvT|V2T0l3ME2yMlgyKM7:TR?= MoHxNlQxOTV|Mke=
NCI60 MUfDfZRwfG:6aXOgRZN{[Xl? NYDnOplEPzJiaB?= NV21N3hjTE2VTx?= MoD3S2k2OD13Lkeg{txO NVTYNZpoOjRyMUWzNlc>
MALME-3M MojLR5l1d3SxeHnjJGF{e2G7 M1u0W|czKGh? NUPN[FBYTE2VTx?= NEHXXGZIUTVyPU[uOlEh|ryP M2HKNVI1ODF3M{K3
KM12 NITUeY9EgXSxdH;4bYMhSXO|YYm= MXG3NkBp NYG1XXBYTE2VTx?= NXW4ZpFVT0l3ME23MlQ1KM7:TR?= MoHTNlQxOTV|Mke=
SW620 M1\VVWN6fG:2b4jpZ{BCe3OjeR?= Ml\lO|IhcA>? NH[zfGtFVVOR MYfHTVUxRThwNEOg{txO MY[yOFAyPTN{Nx?=
RXF 393NL MmT5R5l1d3SxeHnjJGF{e2G7 NGnsXII1KGSjeYO= MUDEUXNQ MVrJR|UxRTBwMEKxO{DPxE1? NX;JdpVrOjN{NUOwO|Q>
LXFA 983L M3y4TmN6fG:2b4jpZ{BCe3OjeR?= NXnGPVdZPCCmYYnz NXHzTZhLTE2VTx?= Mo\aTWM2OD1yLkC1OlUh|ryP NUHyd21LOjN{NUOwO|Q>
PRXF DU145 NVvFS3dwS3m2b4TvfIlkKEG|c3H5 NHLVd4k1KGSjeYO= M{X5d2ROW09? MXLJR|UxRTBwME[yN{DPxE1? NWTFSGliOjN{NUOwO|Q>
PAXF 1657L M2fFXGN6fG:2b4jpZ{BCe3OjeR?= NGrnVJY1KGSjeYO= MUPEUXNQ NHHyZ|ZKSzVyPUCuNVIyKM7:TR?= MlXXNlMzPTNyN{S=
CXF 1103L M1:yWmN6fG:2b4jpZ{BCe3OjeR?= NXzOcWJUPCCmYYnz M3\6UWROW09? MVfJR|UxRTRwM{[g{txO MlnaNlMzPTNyN{S=
GXF251L NXXRSI53S3m2b4TvfIlkKEG|c3H5 NWTMPXh{PCCmYYnz M{PtV2ROW09? MUDJR|UxRTJwMkWg{txO M3jHOVI{OjV|MEe0
NCI-H23 NFr5N5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHr3Ulg4OiCq Mof1SG1UVw>? MXPJR|UxRTJwMkeg{txO MkfhNlM2OjFyMkC=
HCT116 NY\hc4lOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnpd29OPzJiaB?= MYfEUXNQ NUfXc2ZnUUN3ME2yMlMh|ryP Mke1NlM2OjFyMkC=
MCF7 NYi2UldbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYO3NkBp NHvBN|BFVVOR M1vtTWlEPTB;Mj61O{DPxE1? M2e3cFI{PTJzMEKw
NCI-H460 M1f3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXW3NkBp NG\XdHZFVVOR Mmm0TWM2OD16Lkm5JO69VQ>? NXL2V3NkOjN3MkGwNlA>
DLD1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXSR|Q4OiCq M3vUVmROW09? M1ntSWlEPTB;ND62JO69VQ>? NIrmUJgzOzV4N{m2NC=>
NCI-H661 M4LudGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFn2O5Y4OiCq NWfoOHV2TE2VTx?= Mnf1TWM2OD15Lkig{txO NHLmfGQzOzV4N{m2NC=>
A549 NHjHTYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jIPVczKGh? M13V[GROW09? MlHsTWM2OD16LkKg{txO Mo\yNlM2Pjd7NkC=
U937 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUS3NkBp M2T6RWROW09? Ml7HTWM2OD1zMj6yJO69VQ>? NHrZb|gzOzV4N{m2NC=>
HEK293 MW\GeY5kfGmxbjDBd5NigQ>? M33X[VExyqEQvF2= M2fQ[GROW09? M4XqO2lv\HWlZYOgZolv\GmwZzDh[oZqdmm2eTD0c{BpfW2jbjDmeYxtNWynbnf0bEBJcXNvdHHn[4VlKE27dEGgb4lv[XOnIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNid3n0bEBKSzVyIH;mJFAvODZ|zszN MYCyNlc4ODZzMB?=
HUVEC MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTNRmFPOC5zNdMg{txO MlvzO|IhcA>? Mk\4SG1UVw>? M4nCbGlv\HWlZYOgZY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliaX6gTHVXTUNiY3:tZ5VtfHW{ZXSge4l1cCC4YYPjeYxieiC|bX;veIghdXW|Y3zlJINmdGy|IHHzd4V{e2WmIHHzJGlvcGmkaYTpc44hd2ZiY3XscEBoem:5dHigZZQhOC5zNTD1US=> NFT1eIMzOjh3M{m5Ny=>
HUVEC MoPTSpVv[3Srb36gRZN{[Xl? NXTUZ4F4OTYEoN88US=> MmDNO|IhcA>? NXfnNFgzTE2VTx?= NYLOUFNZUW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO|ZXSgZZMhUW6qaXLpeIlwdiCxZjDu[ZR4d3KtIH\vdo1ifGmxbjDheEAyNjhidH:gNVUhfU1? MlroNlI5PTN7OUO=
Plasmodium falciparum M37vTmZ2dmO2aX;uJGF{e2G7 NV7ucGdWOTEEoN88US=> M4rFSlE2KG2rbh?= MWDEUXNQ NYrNcFIxUW6qaXLpeJMhWGyjc33v[Il2dSCoYXzjbZBienWvIIDyc4xq\mW{YYTpc44h[nliaX7obYJqfGmwZzD0bIUhTnWwY4Tpc44hd2ZiUH\DSHBMOSCycn;0[YlvKHerdHigTWM2OCCxZjCxMlE4|ryP MoPTNlQ2PTB|M{C=
PC3 NEjzTGFHfW6ldHnvckBCe3OjeR?= MUiwMlEh|ryP NUH3bnFLPSCq M1OwdGROW09? Mn:wTY5pcWKrdIOgbJVu[W5iUFOzJINmdGxiYXTo[ZNqd25iYYSgNVAxKG6P M1fJfFE6PDZ{OUe1
DU145 M4i3cGZ2dmO2aX;uJGF{e2G7 MW[wMlEh|ryP NWPnc5R[PSCq NXTmRnpRTE2VTx?= MkX2TY5pcWKrdIOgbJVu[W5iRGWxOFUh[2WubDDh[Ihme2mxbjDheEAyODBibl2= NGTMVG4yQTR4Mkm3OS=>
PC3 NW\BWW53U2mwYYPlJGF{e2G7 M4jJNFAvOSEQvF2= Ml3SOUBp MkfuSG1UVw>? NGXMVnBKdmirYnn0d{BkW3KlIHnuJIh2dWGwIGDDN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhW3KlIGm0NVYhdGW4ZXygZZQhOTByIH7N NVLpbHBkOTl2NkK5O|U>
DU145 MnfsT4lv[XOnIFHzd4F6 MWKwMlEh|ryP NUjGVpJsPSCq NHvsb2NFVVOR NXnvWWpQUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiU4LjJHk1OTZibHX2[Ywh[XRiMUCwJI5O MoHINVk1PjJ7N{W=
PC3 MlvYT4lv[XOnIFHzd4F6 M4fqRlAvOSEQvF2= NF7Md3Y2KGh? M{XrPGROW09? MXnJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgSmFMKFl3N{[vXVU4PyCuZY\lcEBifCBzMECgcm0> M{XmcVE6PDZ{OUe1
DU145 MV7LbY5ie2ViQYPzZZk> NEjXZ2IxNjFizszN Mn:yOUBp MYPEUXNQ NIjPeo1KdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCIQVugXVU4Pi:\NUe3JIxmfmWuIHH0JFExOCCwTR?= NYLzUGdVOTl2NkK5O|U>
Huh7 NYnaO2plSW62aY\pdoFtKEG|c3H5 NX:y[ZFGOi53IN88US=> MVy0JIRigXN? NXyzS5RXTE2VTx?= MVnJcohq[mm2czD2bZJidCC|cILlZYQhcW5iRHXu[5VmKH[rcoXzMYlv\mWldHXkJIh2dWGwIFj1bFch[2WubIOgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1? MWOxO|M3ODZ5Nh?=
C6/36 M3HxeWFvfGm4aYLhcEBCe3OjeR?= NFPwc3ozNjVizszN MYi0JIRigXN? NIjYb5pFVVOR NELwNGNKdmirYnn0d{B3cXKjbDDzdJJm[WRiaX6gSIVv\3WnII\pdpV{NWmwZnXjeIVlKGG|aXHuJJRq\2W{IH3vd5F2cXSxIFO2M|M3KGOnbHzzJIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDv[kB3cXKjbDDlcpZmdG:yZTDwdo91\WmwIIfpeIhqdiCyZYLpcpVkdGWjcjDy[Ydqd25iYYSgNk42KHWP MXixO|M3ODZ5Nh?=
U937 NYS0ZYJMTnWwY4Tpc44hSXO|YYm= MVSxJO69VQ>? MUWxJIg> MlHvSG1UVw>? NWrrVIJWWmWmdXPld{Bj[XOjbDDUUmZidHCqYTDy[Yxm[XOnIHnuJIh2dWGwIGW5N|ch[2WubIO= NHu3dJcyPzZ6NEC5PS=>
U937 NHniZ|RHfW6ldHnvckBCe3OjeR?= Mn\SNUDPxE1? M4KxZ|EhcA>? M3XU[2ROW09? MXPS[YR2[2W|IFzQV{1qdmS3Y3XkJHRPTmGucHjhJJJmdGWjc3WgbY4hcHWvYX6gWVk{PyClZXzsdy=> MU[xO|Y5PDB7OR?=
murine mast cell M33xbGZ2dmO2aX;uJGF{e2G7 MWmxJO69VQ>? M{PxTVI1KGh? NVLueFVmTE2VTx?= M1jEXmlvcGmkaYTzJIFvfGmpZX6tbY5lfWOnZDDJUFYhe2WlcnX0bY9vKGmwIFnnSUBxemmvZXSgcY92e2VibXHzeEBk\WyuczDheEAyKHWP NIr4OIUyPzZ6NEC5PS=>
BV-173 MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\uVYFiUUN3ME2wMlAxODByMEGwPUDPxE1? M1zob3NCVkeHUh?=
K-562 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnxUlFEUUN3ME2wMlAxODByMEK2OkDPxE1? M2LMUHNCVkeHUh?=
BL-70 NXPFOGlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Ht[WlEPTB;MD6wNFAxODB6MkKg{txO MoTxV2FPT0WU
EM-2 NF\aOVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPrS3pKSzVyPUCuNFAxODBzMEig{txO NWDRd|ZSW0GQR1XS
LAMA-84 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfpfHJKSzVyPUCuNFAxODB|MkGg{txO NYfqUmU3W0GQR1XS
MEG-01 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3OzN2lEPTB;MD6wNFAxODl6IN88US=> NHvJRY9USU6JRWK=
EoL-1-cell MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwMECwNFE{OSEQvF2= NUXiU4JqW0GQR1XS
CTV-1 Mn7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknFTWM2OD1yLkCwNFA1ODRizszN MkfMV2FPT0WU
TE-15 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnzTWM2OD1yLkCwOVg6KM7:TR?= M4ruXnNCVkeHUh?=
NOS-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1K3OGlEPTB;MD6wNFYyOyEQvF2= M{nCbHNCVkeHUh?=
D-336MG NIH6eJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITtcnhKSzVyPUCuNFA3OyEQvF2= NVfqVYRpW0GQR1XS
LB1047-RCC MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwMEC5PFkh|ryP NIHKRmVUSU6JRWK=
LB996-RCC NYf6e2lQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\1OpVKSzVyPUCuNFA6QTFizszN NVOxNHkxW0GQR1XS
SW982 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13kfmlEPTB;MD6wNVEyPSEQvF2= NULreYJ[W0GQR1XS
TK10 NVPWXYtnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfnPY5KSzVyPUCuNFEyPzRizszN NEO4b5pUSU6JRWK=
A704 NIe1ToJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2D0ZWlEPTB;MD6wNVQ6OSEQvF2= MmDtV2FPT0WU
TE-8 M2PHb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PvR2lEPTB;MD6wNVU4PiEQvF2= M{fIWnNCVkeHUh?=
DOHH-2 NUHYbYhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzpeFhsUUN3ME2wMlAyPzF7IN88US=> M17qcHNCVkeHUh?=
HOP-62 NVfYbHJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEOySG9KSzVyPUCuNFE5OzRizszN M1;yXXNCVkeHUh?=
TE-12 Mln2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnxSXdKSzVyPUCuNFE5PjFizszN NYLP[VNTW0GQR1XS
KGN MmnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXQTWM2OD1yLkCxPVQzKM7:TR?= NXr1S5ozW0GQR1XS
NCI-H1648 MkXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4[4eWlEPTB;MD6wNlAyOSEQvF2= NX7FbpZLW0GQR1XS
OS-RC-2 M{TNWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDmc2tKSzVyPUCuNFIxOyEQvF2= NEPReZFUSU6JRWK=
GB-1 NEDtVINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWL4d4ZWUUN3ME2wMlAzOTV5IN88US=> Mnr2V2FPT0WU
RXF393 NIXZNG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnj3TWM2OD1yLkCyN|U4KM7:TR?= MnLsV2FPT0WU
LC-2-ad MmHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXryNWZvUUN3ME2wMlAzPTh4IN88US=> NHHKb29USU6JRWK=
KS-1 NEfCOZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDNTWM2OD1yLkCyO|Mh|ryP NF7EVJhUSU6JRWK=
ETK-1 M1XhTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\PNWlEPTB;MD6wNlg{OiEQvF2= MlH2V2FPT0WU
SW954 MnHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwMEK5Nlch|ryP NVXoO4lvW0GQR1XS
Becker NFjS[ZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3MTWM2OD1yLkCzNFA{KM7:TR?= MmnaV2FPT0WU
MZ1-PC MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoniTWM2OD1yLkCzNVE6KM7:TR?= MnOzV2FPT0WU
ES6 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmThTWM2OD1yLkCzNVk{KM7:TR?= MWrTRW5ITVJ?
KURAMOCHI NEPLToZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjFTWM2OD1yLkCzOFg4KM7:TR?= NVztZ5NGW0GQR1XS
CGTH-W-1 NHjNSnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DtbWlEPTB;MD6wN|U1QCEQvF2= Ml;KV2FPT0WU
VA-ES-BJ NGS2N3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3ITWM2OD1yLkCzPVAzKM7:TR?= MYHTRW5ITVJ?
LXF-289 M3\4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\CTWM2OD1yLkCzPVU3KM7:TR?= NFTucVNUSU6JRWK=
MPP-89 MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwMESwOFkh|ryP MmT2V2FPT0WU
SW872 M{XU[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnWbo9SUUN3ME2wMlA1OTZzIN88US=> M1ziOHNCVkeHUh?=
SNB75 MmjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLYTWM2OD1yLkC0OFM2KM7:TR?= MnP3V2FPT0WU
PSN1 NVfhN2xPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorXTWM2OD1yLkC0OFc1KM7:TR?= M2X2RXNCVkeHUh?=
LB831-BLC MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrhdI9SUUN3ME2wMlA1PjB7IN88US=> MnfqV2FPT0WU
MFH-ino MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwMES3NlQh|ryP MXLTRW5ITVJ?
TGBC24TKB M1XWPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHsVY5KSzVyPUCuNFQ4PjFizszN MV3TRW5ITVJ?
A388 NG\RVZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojNTWM2OD1yLkC1NFk2KM7:TR?= MmK0V2FPT0WU
BB30-HNC NUPwUHltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1OzUWlEPTB;MD6wOVQ{PyEQvF2= NH;qXY9USU6JRWK=
GI-ME-N NUDYbmpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\Jd3FKSzVyPUCuNFYyOThizszN M3r1cHNCVkeHUh?=
TGBC1TKB NYrVdmFrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTBwME[xOlQh|ryP M3TRdXNCVkeHUh?=
TE-10 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHQTWM2OD1yLkC2N|U4KM7:TR?= M1rpRnNCVkeHUh?=
A498 NEjVS5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUH4VWhLUUN3ME2wMlA4Ojh2IN88US=> MnXTV2FPT0WU
TE-11 M2jPc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkj6TWM2OD1yLkC3PFU5KM7:TR?= MmnkV2FPT0WU
BB65-RCC MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LyV2lEPTB;MD6wPFIzPyEQvF2= NFnxTXhUSU6JRWK=
C2BBe1 M1LaZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrZdZlKSzVyPUCuNFg{ODhizszN NWf0[|JiW0GQR1XS
NCI-H747 NUXscIUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTBwMEizOlIh|ryP NHT5OI9USU6JRWK=
IST-MES1 NGezboRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1npXGlEPTB;MD6wPFU2OiEQvF2= NYTZZW9MW0GQR1XS
KALS-1 NGqxR3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rsbmlEPTB;MD6wPVQ6KM7:TR?= MWPTRW5ITVJ?
GCIY NF;INVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\sbmlEPTB;MD6wPVY2PiEQvF2= NF;N[Y9USU6JRWK=
RL95-2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:xeVhlUUN3ME2wMlExOzhizszN M{LwZnNCVkeHUh?=
TE-1 M1rz[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTBwMUC1OEDPxE1? NXXsZYZ4W0GQR1XS
NCI-H1355 MkfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnSRZlKSzVyPUCuNVExOjhizszN NGH6VWZUSU6JRWK=
SW962 NFPnPVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnEZ|JQUUN3ME2wMlEyOjl{IN88US=> NGf5RW5USU6JRWK=
KLE NIroW5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILDR4FKSzVyPUCuNVE{OTdizszN MXfTRW5ITVJ?
MC116 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1:xXmlEPTB;MD6xNVQyKM7:TR?= M1TPVHNCVkeHUh?=
NMC-G1 M3m5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TKPGlEPTB;MD6xNVYxPiEQvF2= MWPTRW5ITVJ?
KU812 M2DqfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTBwMUG4PFMh|ryP NGTHcHhUSU6JRWK=
COLO-829 NXmzd3ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3ftWGlEPTB;MD6xNlIyOyEQvF2= M33WV3NCVkeHUh?=
NTERA-S-cl-D1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3SxTmlEPTB;MD6xNlI5OyEQvF2= MWTTRW5ITVJ?
IST-MEL1 MlX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTBwMUO0OUDPxE1? M1LGUnNCVkeHUh?=
MLMA M3vy[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjYTWM2OD1yLkG0NFMzKM7:TR?= MkXlV2FPT0WU
LS-123 NID0RWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3KTWM2OD1yLkG0NFY1KM7:TR?= NE\zcJRUSU6JRWK=
LB2518-MEL MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXxSJBKSzVyPUCuNVQyPjJizszN Mle2V2FPT0WU
NB69 MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXKelNKSzVyPUCuNVQ1OzZizszN Moi1V2FPT0WU
8-MG-BA MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHKTWM2OD1yLkG1OFU5KM7:TR?= MUTTRW5ITVJ?
K5 MnzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUX4R5ZJUUN3ME2wMlE3PDh7IN88US=> NX\zUYFPW0GQR1XS
KINGS-1 NInSNmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrzUWx3UUN3ME2wMlE3PjZ4IN88US=> NI\YU3NUSU6JRWK=
SF268 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfQepNjUUN3ME2wMlE4PDB2IN88US=> NWnqNG9HW0GQR1XS
PF-382 Mmr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTBwMUe2O|gh|ryP M3jBVHNCVkeHUh?=
SH-4 NVrYSIdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfZfY9KSzVyPUCuNVg1OTNizszN M{D5OHNCVkeHUh?=
NALM-6 NYPNU4tYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPVcnN6UUN3ME2wMlE6Ojl3IN88US=> Ml7NV2FPT0WU
CP66-MEL MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXNTWM2OD1yLkG5OVMyKM7:TR?= M1joXnNCVkeHUh?=
697 M3vqeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Dve2lEPTB;MD6xPVk5PyEQvF2= NX25N2ZIW0GQR1XS
CP67-MEL NV\SVlBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWGxW41lUUN3ME2wMlIxPDh6IN88US=> NVPHSI16W0GQR1XS
DSH1 M17MSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzETWM2OD1yLkK0NFAyKM7:TR?= NIHEPHBUSU6JRWK=
HCE-4 NGjxOHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXX2UHZ5UUN3ME2wMlI3PDN7IN88US=> MnHsV2FPT0WU
MZ2-MEL NFv2TnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjlTWM2OD1yLkK4OVM4KM7:TR?= NFLxTohUSU6JRWK=
BL-41 Mm\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDVTWM2OD1yLkK5NVI{KM7:TR?= NX3ZeFJZW0GQR1XS
HUTU-80 M3\GdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIm0RWlKSzVyPUCuN|E1OiEQvF2= MkPWV2FPT0WU
LOXIMVI NEfldoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DUTGlEPTB;MD6zNVUxOyEQvF2= MX3TRW5ITVJ?
no-10 NFTRfpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIG5XoFKSzVyPUCuN|E6OzFizszN MnO5V2FPT0WU
KARPAS-422 NHe2V2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HqT2lEPTB;MD6zN|k6PyEQvF2= MXfTRW5ITVJ?
SW684 NH;NOnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljOTWM2OD1yLkO0PVgh|ryP M1XV[nNCVkeHUh?=
SF126 MkH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zsdWlEPTB;MD6zOVQyKM7:TR?= M{PLdHNCVkeHUh?=
D-263MG NUfIRVNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwM{[yNlQh|ryP NWPCNVIyW0GQR1XS
OVCAR-4 M4PNOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYewPVh4UUN3ME2wMlM4PDN|IN88US=> M{O0bXNCVkeHUh?=
BB49-HNC MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwM{i1PVkh|ryP NXjyPFBxW0GQR1XS
ONS-76 NEj4SplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVr6NI1KUUN3ME2wMlQzQTVzIN88US=> NYr1do1PW0GQR1XS
MZ7-mel NXnNTW1NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkKwTWM2OD1yLkS3PVEyKM7:TR?= M2TBPXNCVkeHUh?=
RCC10RGB MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PjZmlEPTB;MD60PVEyKM7:TR?= M12zfnNCVkeHUh?=
BOKU NYXKcJZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HSeGlEPTB;MD60PVE{OyEQvF2= MUHTRW5ITVJ?
no-11 NHTWO2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DKOWlEPTB;MD61NFIzQCEQvF2= MVTTRW5ITVJ?
IST-SL2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rIU2lEPTB;MD61NFMxOiEQvF2= MVXTRW5ITVJ?
RKO MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwNUK5OlYh|ryP M322OXNCVkeHUh?=
HT-144 NFrwZXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fvNWlEPTB;MD61N|YxQSEQvF2= MVvTRW5ITVJ?
NCI-H446 NF\KeJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnMeIhKSzVyPUCuOlI4PiEQvF2= M1fYbHNCVkeHUh?=
QIMR-WIL MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWD1NGU4UUN3ME2wMlcxPjJ7IN88US=> Mlz5V2FPT0WU
MHH-PREB-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rtOmlEPTB;MD63OFQ3QSEQvF2= MnzQV2FPT0WU
EW-16 NVTKUIN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTBwN{[xO|gh|ryP MoH4V2FPT0WU
EW-24 M2TxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjLbVhJUUN3ME2wMlc5OTZ3IN88US=> Mo\SV2FPT0WU
LB373-MEL-D Ml3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrKZVFKSzVyPUCuPFI2ODhizszN M4m1SXNCVkeHUh?=
TE-9 NGPsdGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3YTWM2OD1yLki3OVMzKM7:TR?= NWjNNmp4W0GQR1XS
A3-KAW NXGwdXd7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwOUi0OVIh|ryP NUDsfVV3W0GQR1XS
A101D MlfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHaTWM2OD1zLkCzNFQ{KM7:TR?= NU[0VJNIW0GQR1XS
OCUB-M NHTUTFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTITWM2OD1zLkC0OFEzKM7:TR?= Mo\5V2FPT0WU
ES4 NVK1ZoJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnNbI1wUUN3ME2xMlA2OTR3IN88US=> NGGzcXBUSU6JRWK=
TE-6 NYjRS284T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TDbmlEPTB;MT6yNVIzPiEQvF2= M{jze3NCVkeHUh?=
D-502MG NVHGUmxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnTe3NxUUN3ME2xMlI{Ozd4IN88US=> NGjFfYhUSU6JRWK=
KNS-42 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDaTWM2OD1zLkK0OFEzKM7:TR?= NXnqd4lvW0GQR1XS
SNU-C2B NYT5dFRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXleGZVUUN3ME2xMlMxPTh7IN88US=> NYnH[2dsW0GQR1XS
NCI-H1838 Mlu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmK0TWM2OD1zLkOwO|M{KM7:TR?= MVjTRW5ITVJ?
NKM-1 NWHQcIVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTFwM{C4OVkh|ryP MnraV2FPT0WU
GI-1 MkL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\oTWlEPTB;MT6zOlIzKM7:TR?= NGfqUYxUSU6JRWK=
NB5 NXj1bFFxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTETWM2OD1zLkO5PFI4KM7:TR?= NWjOc3k6W0GQR1XS
CAS-1 MoL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILYT2xKSzVyPUGuOFA6QTJizszN M2jZNXNCVkeHUh?=
HCE-T NXv6OXZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnUPWFKUUN3ME2xMlU3PzF2IN88US=> M1L5THNCVkeHUh?=
SBC-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTFwNUe5PFQh|ryP M1XKe3NCVkeHUh?=
JiyoyeP-2003 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmT0TWM2OD1zLkezOFY3KM7:TR?= NHPQWVVUSU6JRWK=
TE-5 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zIOGlEPTB;MT63PVE{QSEQvF2= MX;TRW5ITVJ?
CAN NYHKPGsyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPNdo5KSzVyPUGuPFIzPTJizszN Mm\uV2FPT0WU
SK-UT-1 NVn0ZVI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjtRoVKSzVyPUKuNVY3QTNizszN M3v1WHNCVkeHUh?=
JVM-2 M2rwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DMbmlEPTB;Mj6zOlI5PCEQvF2= Mlv5V2FPT0WU
LB771-HNC MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTJwNUe1OVEh|ryP M37SOXNCVkeHUh?=
NCCIT M1G1bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn31TWM2OD1{Lki2OlE3KM7:TR?= M{X1PXNCVkeHUh?=
NCI-H2126 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXQN2tYUUN3ME2yMlg4PTV{IN88US=> NWnBfoo3W0GQR1XS
Calu-6 NHrRSotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTIV4hKSzVyPUOuNFU4PDFizszN NEDLbnVUSU6JRWK=
SK-LMS-1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTNwMUG4PFYh|ryP M2HSSnNCVkeHUh?=
ARH-77 NF3ZbZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnZTJdKSzVyPUOuOFY6OTVizszN NW\iOmZnW0GQR1XS
NB17 Ml3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIL3cIFKSzVyPUOuOlM5PDdizszN MXPTRW5ITVJ?
A253 M4P6Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTNwN{OyOFYh|ryP MlrKV2FPT0WU
OPM-2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLoTWM2OD12LkK3Olg2KM7:TR?= M3;lfHNCVkeHUh?=
MV-4-11 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTRwM{[0OVQh|ryP MYHTRW5ITVJ?
SR NFL0[4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTHUY9KSzVyPUSuOFk6PTRizszN M1OwfXNCVkeHUh?=
KG-1 MmC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTRwNkC4OFUh|ryP M3G1eXNCVkeHUh?=
OCI-AML2 NVrITJFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M124emlEPTB;NT64OlE2PCEQvF2= NVnPPHkzW0GQR1XS
D-247MG MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfnTWM2OD14LkGyOVE6KM7:TR?= MX\TRW5ITVJ?
DJM-1 NHW1cGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkD4TWM2OD14LkS4OVU5KM7:TR?= MVXTRW5ITVJ?
RPMI-6666 M{fuW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYO0UlA5UUN3ME23MlI4ODZ5IN88US=> MXPTRW5ITVJ?
KARPAS-45 NFW0SpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7KTWM2OD15LkWxOlcyKM7:TR?= NG\tTpFUSU6JRWK=
LP-1 NUHtWIRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nVN2lEPTB;Nz61OFc5OiEQvF2= MkHjV2FPT0WU
RS4-11 NXLBOmtpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTdwNkW3PFch|ryP MXPTRW5ITVJ?
DU-4475 MnvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHwb|RKSzVyPUiuNlE3PTJizszN M1TzRXNCVkeHUh?=
MONO-MAC-6 NVTzT5RMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmq4TWM2OD16LkK3NFY3KM7:TR?= MW\TRW5ITVJ?
NCI-SNU-16 NFLkVHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRThwNU[xNlgh|ryP Ml3RV2FPT0WU
SJSA-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRThwN{K4NFUh|ryP NXTKdYM1W0GQR1XS
MMAC-SF MlH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXVTWM2OD16Lke5N|A4KM7:TR?= NUj4W2ZuW0GQR1XS
SK-NEP-1 M2jMdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRThwOEmxOVUh|ryP Mmf5V2FPT0WU
J-RT3-T3-5 M3T4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\LVWlEPTB;OD65OlUzQSEQvF2= MWPTRW5ITVJ?
SKM-1 M1PINWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYq0W|lqUUN3ME25MlAyPzN2IN88US=> M1X6eXNCVkeHUh?=
LB2241-RCC NG\tSXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TBW2lEPTB;OT6wNlAyOiEQvF2= NUeyTVZvW0GQR1XS
SIG-M5 M4fDOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrqTWM2OD17LkCyOFk{KM7:TR?= MojHV2FPT0WU
EVSA-T NYK5WnB7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPubmF1UUN3ME25MlI4Pzl|IN88US=> NHz0TldUSU6JRWK=
GT3TKB NHTtUYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:5fWxKSzVyPUmuN|U2PDZizszN Mnj3V2FPT0WU
NB6 NEDuWZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITMN49KSzVyPUmuPVIzPTlizszN Mo\WV2FPT0WU
EHEB NGfjSmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fVTGlEPTB;MUCuNFY2PiEQvF2= M4\RbnNCVkeHUh?=
HEL NXXqd|NmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHIO|dMUUN3ME2xNE41Pzd4IN88US=> M3rHeXNCVkeHUh?=
ALL-PO NW\NZ45tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXNTWM2OD1zMD63PVM5KM7:TR?= NYHEbVQ3W0GQR1XS
TGW M3fMdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTFzLkK4Nlgh|ryP MnLOV2FPT0WU
BC-3 MmDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PYWmlEPTB;MUKuNVE{QCEQvF2= NUS3c4d6W0GQR1XS
IA-LM NWDwcYw5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnBTWM2OD1zMj60OFQ2KM7:TR?= MlzKV2FPT0WU
UACC-257 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DXeWlEPTB;MUKuPVE6QCEQvF2= M1rv[3NCVkeHUh?=
KP-N-YS MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HMOGlEPTB;MUKuPVI5OyEQvF2= MmX1V2FPT0WU
Raji MmHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfEcIJKSzVyPUGzMlc1QTdizszN MkfPV2FPT0WU
SF539 MlTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjI[HJCUUN3ME2xN{45PTV5IN88US=> NXy1b2J3W0GQR1XS
DMS-153 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTYTWM2OD1zND6wNFI5KM7:TR?= NEmzeJpUSU6JRWK=
L-540 NUPMcHFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIGwcGVKSzVyPUG1MlA3PzJizszN NHf0TWxUSU6JRWK=
MN-60 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HqWmlEPTB;MUWuNVk4QSEQvF2= MXHTRW5ITVJ?
RPMI-8866 NGjTXnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPWR2FKSzVyPUG3MlQ1PTRizszN NWPibmpyW0GQR1XS
NCI-H510A NYDY[ZJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEW2XG5KSzVyPUG5MlM6PzNizszN MWLTRW5ITVJ?
NB13 Ml;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoKxTWM2OD1zOT60PFc4KM7:TR?= M{LnXnNCVkeHUh?=
HAL-01 Mo\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvOTWM2OD1zOT63OVQ{KM7:TR?= MnHuV2FPT0WU
NCI-H720 M{PEe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTJyLkK3N|Mh|ryP MVTTRW5ITVJ?
REH MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7FNHhKSzVyPUKwMlY{PTdizszN Mni4V2FPT0WU
KNS-81-FD MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHCTWM2OD1{Mz6xOFYh|ryP NXfYc4pPW0GQR1XS
HC-1 M3\4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rKcWlEPTB;MkSuOVU2OSEQvF2= M{LPXHNCVkeHUh?=
NCI-H2141 MlPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnS4TWM2OD1{ND63O|U1KM7:TR?= NF\pWoJUSU6JRWK=
MOLT-4 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrmUIpKSzVyPUK2MlY4PTNizszN NVXhSWJbW0GQR1XS
OMC-1 NYDGTGJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPSdJhKSzVyPUK3MlE1OjJizszN NIDpNHJUSU6JRWK=
LC-1F NXXBc4R{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDBXmtMUUN3ME2yO{4{OjR3IN88US=> MlPQV2FPT0WU
NCI-H1304 MmLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTJ6LkG2Nlgh|ryP MUnTRW5ITVJ?
BC-1 NIPrd41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnsN3FDUUN3ME2yPE43PTFizszN M1X5cnNCVkeHUh?=
NCI-H64 NVHmNFFwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoW3TWM2OD1{OT62NlU{KM7:TR?= NULOTVBQW0GQR1XS
MOLT-16 NUG1V2JUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLXfXJWUUN3ME2yPU43Ojl{IN88US=> MVjTRW5ITVJ?
U-87-MG MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTOTWM2OD1|MD63OlYh|ryP NVPKbFlsW0GQR1XS
GAK MmXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fjeGlEPTB;M{GuNlY5PiEQvF2= NHzl[VhUSU6JRWK=
ES8 NU\5V41jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkexTWM2OD1|Mj6xNlUzKM7:TR?= MUDTRW5ITVJ?
HCC1599 NHXJfY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnWe|ZyUUN3ME2zNk4{OzJ3IN88US=> MljEV2FPT0WU
EB-3 M{XheGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nFVGlEPTB;M{SuN|EyPyEQvF2= NXjCeItvW0GQR1XS
HCC1187 NEXSO4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\ESXo2UUN3ME2zOU45ODV{IN88US=> NI\TR5BUSU6JRWK=
SK-PN-DW NG\TZVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mni5TWM2OD1|Nj6xPVQ{KM7:TR?= M2nicXNCVkeHUh?=
JVM-3 NVfq[WF6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkP0TWM2OD1|Nz6yN|M5KM7:TR?= MlH5V2FPT0WU
HCC2157 NX6zN5NLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInrVpdKSzVyPUO3Mlk6PDZizszN M4XvWXNCVkeHUh?=
A4-Fuk MljmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWS1fJNHUUN3ME2zPE4yODB7IN88US=> NX7sfJFlW0GQR1XS
COR-L279 NGnyd|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXp[VFKSzVyPUSwMlI5PTFizszN MnjCV2FPT0WU
DEL M{DBTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nSR2lEPTB;NEGuPVA5PiEQvF2= MXrTRW5ITVJ?
NCI-H1395 Moi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGS2[mJKSzVyPUSyMlAyPjNizszN NFnrVXZUSU6JRWK=
MHH-NB-11 NUPkSppWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXezTJI3UUN3ME20N{4xQDF6IN88US=> MUPTRW5ITVJ?
NCI-H2107 M3SyfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWGy[4h[UUN3ME20N{41QDR4IN88US=> M4foUnNCVkeHUh?=
NEC8 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTR2LkOzOkDPxE1? M1q3fnNCVkeHUh?=
COLO-684 NWTuWFB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrxTWM2OD12Nj6yNlU5KM7:TR?= MUXTRW5ITVJ?
LS-411N NGPi[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTR6LkS3OFgh|ryP MXzTRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416); 

PubMed: 23049975     


Protein levels of phosphorylated c-Abl (Tyr245), c-Abl, phosphorylated c-Src (Tyr416), c-Src, and GAPDH in NSC-34 cells overexpressing human wild-type or mutant SOD1s treated with various concentrations of dasatinib were measured by western blot. Cells were cultured in serum-free culture medium with doxycycline (Dox, 2 µg/ml), and western blot was performed at 24 h after dasatinib addition.

p27 / p21; 

PubMed: 20145167     


Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for 48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for comparable protein loading.

p-FAK / p-STAT3; 

PubMed: 23721490     


The effect of dasatinib in cell signalling. Western blot analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC cell lines after 24 hours treatment of dasatinib. The cell lines were arranged according to their IC50 to dasatinib. The top three were most sensitive, the bottom 3 were least sensitive.

cleaved caspase 3; 

PubMed: 20145167     


Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves as loading control.

23049975 20145167 23721490
Growth inhibition assay
IC50; 

PubMed: 23721490     


9 HCC cell lines were exposed to the dedicated concentrations of dasatinib for 72 hours, and IC50 was tested by MTS. Results represent the mean (± SD) of three experiments.

23721490
Immunofluorescence
SRC / Met; 

PubMed: 26517812     


Immunocytochemistry of SRC and Met localization. Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively.

F-actin / Actinin-4 / Paxillin; 

PubMed: 31053734     


Conditionally immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei (Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars = 50 µm). Podocytes treated with dasatinib showed a marked decrease in cell-to-cell contacts, cell size and number of focal adhesions.

α-tubulin; 

PubMed: 26517812     


Combination of dasatinib and crizotinib impedes the formation of the α-tubulin-labeled mitotic spindle. LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.

26517812 31053734
ELISA
TNF-α; 

PubMed: 17684099     


U937 cells were differentiated with vitamin D3, pretreated with the indicated concentrations of drugs for 1 h and stimulated with LPS for 6 h. TNF-α secretion was measured by ELISA. The graph shows the mean of two experiments done in duplicate.

E-selectin; 

PubMed: 31110200     


HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of E-selectin was determined using ELISA (n = 3, ±SEM).

VCAM-1; 

PubMed: 31110200     


HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of VCAM-1 was determined using ELISA (n = 3, ±SEM).

17684099 31110200
体内研究 Dasatinib 作用于LMP2A/MYC 双转基因小鼠,可逆转脾肿大。Dasatinib 作用于TgE小鼠 抑制表达LMP2A 的骨髓B 细胞形成的菌落,且使脾脏变小。使用Dasatinib处理Tg6/λ-MYC 小鼠,与对照组相比,脾脏质量明显降低。Dasatinib 作用于LMP2A/MYC 双转基因小鼠,抑制淋巴结肿大。Dasatinib作用于嫁接LMP2A/MYC双转基因小鼠肿瘤细胞的Rag1KO小鼠,可逆转脾肿大。Dasatinib 作用于表达LMP2A的B 淋巴细胞瘤,抑制Lyn磷酸化。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

激酶自磷酸化分析:

使用野生型和突变型谷胱甘肽S-转移酶(GST)-Abl融合蛋白 (c-Abl氨基酸220-498位) 进行激酶实验。从谷胱甘肽琼脂糖珠中释放GST-Abl融合蛋白,ATP浓度为5 μM。在用于激酶自磷酸化和体外肽底物磷酸化实验前, 用LAR酪氨酸磷酸酶处理GST-Abl 激酶域融合蛋白。在 30oC下温育1小时后,加入1 mM 钒酸钠,激活LAR磷酸酶。进行免疫印迹分析,比较未处理的GST-Abl激酶和去磷酸化的GST-Abl激酶,使用磷酸化的特点抗体4G10来 确认酪氨酸残基完全去磷酸化(>95%),使用c-Abl抗体 CST 2862 来确认GST-Abl激酶的平衡负载。实验测定IC50值时所用Dasatinib浓度为0 nM到32 nM。Dasatinib作用于突变型T315I时浓度达到 1,000 nM。在体外肽底物磷酸化实验中使用相同抑制剂浓度。作用于GST-Src激酶和 GST-Lyn激酶的三种抑制剂的浓度范围相同。
细胞实验: [1]
- 合并
  • Cell lines: Ba/F3细胞系
  • Concentrations: 0 nM-32 nM
  • Incubation Time: 72小时
  • Method: Ba/F3 细胞系重复培养三份,然后与浓度逐渐升高的 Dasatinib 温育72小时。通过MTS活性实验测定细胞增殖。IC50值和IC90值取自三组独立实验的平均值。Dasatinib作用的IC50值和IC90值为0 nM 到32 nM 。Dasatinib 作用于突变型T315I时所需浓度达到200 nM。
    (Only for Reference)
动物实验:[2]
- 合并
  • Animal Models: EμLMP2A(TgE 和Tg6品种),MYC (λ-MYC), 和LMP2A/λ-MYC双转基因小鼠(Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 488.01
化学式

C22H26ClN7O2S

CAS号 302962-49-8
储存条件 粉状
溶于溶剂
别名 BMS-354825

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04063124 Not yet recruiting Drug: Dasatinib + Quercetin Alzheimer Disease The University of Texas Health Science Center at San Antonio|Mayo Clinic December 2019 Phase 1|Phase 2
NCT04115059 Not yet recruiting Drug: Dasatinib Waldenstrom Macroglobulinemia|DASATINIB Jorge J. Castillo MD|Bristol-Myers Squibb|Dana-Farber Cancer Institute November 2019 Phase 1
NCT03318770 Not yet recruiting Drug: Dasatinib and blinatumomab Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto December 2018 --
NCT03625388 Recruiting Drug: Dasatinib Chronic Myelogenous Leukemia Hikma Pharmaceuticals LLC November 5 2018 Phase 2
NCT03193281 Recruiting Drug: Dasatinib|Drug: Imatinib Chronic Myeloid Leukemia University of Auckland New Zealand|Leukaemia & Blood Cancer New Zealand July 17 2017 Phase 2
NCT03041701 Recruiting Drug: Dasatinib|Drug: Ganitumab Rhabdomyosarcoma|Rhabdomyosarcoma- Alveolar|Rhabdomyosarcoma-Embryonal National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7 2017 Phase 1|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • 回答:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • 问题 2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • 回答:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

相关Src产品

Tags: 购买Dasatinib | Dasatinib供应商 | 采购Dasatinib | Dasatinib价格 | Dasatinib生产 | 订购Dasatinib | Dasatinib代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID